Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Achieve Life Sciences, Inc. (ACHV : NSDQ)

• Company Description    Achieve Life Sciences Inc. is a pharmaceutical company. It develops and commercializes cytisine treatment to help people battling nicotine addiction. The Company's product candidates include Custirsen, Apatorsen and OGX-225. Achieve Life Sciences Inc., formerly known as OncoGenex Pharmaceuticals Inc., is based in Bothell, United States. Number of Employees: 28

• Price / Volume Information    Yesterday's Closing Price: $4.69 Daily Weekly Monthly 20 Day Moving Average: 1,250,068 shares Shares Outstanding: 102.66 (millions) Market Capitalization: $481.47 (millions) Beta: 2.25 52 Week High: $6.15 52 Week Low: $2.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 13.01% 7.49% 12 Week -0.85% -8.34% Year To Date -5.63% -14.91%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1040 West Georgia Street Suite 1030 - Vancouver,BC V6E 4H1 CAN ph: 604-210-2217 fax: 425-686-1600 ir@achievelifesciences.com http://www.achievelifesciences.com

• General Corporate Information    Officers Richard Stewart - Chief Executive Officer and President Thomas B. King - Chairman Mark Oki - Chief Financial Officer Jerry Wan - Vice President; Finance Bridget Martell - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 004468500 SIC: 2835 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 102.66 Most Recent Split Date: 7.00 (0.05:1) Beta: 2.25 Market Capitalization: $481.47 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.19 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.90 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 45.09 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 48.65% vs. Previous Quarter: 32.14% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -193.49 12/31/25 - -204.14 09/30/25 - -196.68 ROA 03/31/26 - -111.88 12/31/25 - -121.36 09/30/25 - -118.32 Current Ratio 03/31/26 - 2.62 12/31/25 - 4.39 09/30/25 - 5.14 Quick Ratio 03/31/26 - 2.62 12/31/25 - 4.39 09/30/25 - 5.14 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 0.10 12/31/25 - 0.40 09/30/25 - 0.66 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.87 12/31/25 - 0.52 09/30/25 - 0.26 Debt-to-Capital 03/31/26 - 46.61 12/31/25 - 34.21 09/30/25 - 20.55

Powered by Zacks Investment Research ©